Teton Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-25,000
| Closed | -$55.3K | – | 243 |
|
|
2023
Q2 | $55.3K | Sell |
25,000
-8,700
| -26% | -$18K | 0.02% | 238 |
|
|
2023
Q1 | $85.6K | Sell |
33,700
-800
| -2% | -$1.58K | 0.02% | 249 |
|
|
2022
Q4 | $64.5K | Sell |
34,500
-9,500
| -22% | -$23.7K | 0.02% | 260 |
|
|
2022
Q3 | $113K | Hold |
44,000
| – | – | 0.03% | 260 |
|
|
2022
Q2 | $85K | Hold |
44,000
| – | – | 0.02% | 283 |
|
|
2022
Q1 | $131K | Hold |
44,000
| – | – | 0.02% | 297 |
|
|
2021
Q4 | $198K | Buy |
44,000
+29,000
| +193% | +$138K | 0.03% | 374 |
|
|
2021
Q3 | $73K | Sell |
15,000
-4,000
| -21% | -$22K | 0.01% | 393 |
|
|
2021
Q2 | $130K | Hold |
19,000
| – | – | 0.02% | 383 |
|
|
2021
Q1 | $134K | Hold |
19,000
| – | – | 0.02% | 368 |
|
|
2020
Q4 | $119K | Hold |
19,000
| – | – | 0.02% | 377 |
|
|
2020
Q3 | $103K | Sell |
19,000
-4,000
| -17% | -$19.8K | 0.02% | 366 |
|
|
2020
Q2 | $120K | Sell |
23,000
-2,000
| -8% | -$8.88K | 0.02% | 373 |
|
|
2020
Q1 | $79K | Sell |
25,000
-2,000
| -7% | -$7.38K | 0.01% | 403 |
|
|
2019
Q4 | $109K | Sell |
27,000
-18,000
| -40% | -$62.4K | 0.01% | 430 |
|
|
2019
Q3 | $194K | Sell |
45,000
-47,000
| -51% | -$188K | 0.02% | 425 |
|
|
2019
Q2 | $367K | Sell |
92,000
-18,000
| -16% | -$85.6K | 0.04% | 375 |
|
|
2019
Q1 | $590K | Buy |
110,000
+2,000
| +2% | +$12.9K | 0.06% | 289 |
|
|
2018
Q4 | $554K | Buy |
108,000
+84,000
| +350% | +$638K | 0.06% | 285 |
|
|
2018
Q3 | $233K | Hold |
24,000
| – | – | 0.02% | 428 |
|
|
2018
Q2 | $245K | Buy |
+24,000
| New | +$272K | 0.02% | 413 |
|
Teton Advisors's PRTK Position: Q3 2023 in Review
Teton Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 25,000 shares — an estimated $55.3K sold.
Teton Advisors first reported a position in PRTK in Q2 2018 and held it in 21 quarters. The position peaked at $590K in Q1 2019. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Teton Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Teton Advisors sold 25,000 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $55.3K.
- Teton Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2018 and held it in 21 quarters.
- Teton Advisors's Paratek Pharmaceuticals, Inc. position peaked at $590K in Q1 2019.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Teton Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.